Quote:
Originally Posted by Ackj
Nobody dies from HIV, they die from resulting neutropenic coinfections.  I know what you mean, but I'm not certain that it's really an issue of prevalence but rather current treatments. We have quite a few effective HIV meds now, and in the past few decades we've learned a lot about it. Hep C never really is a big news story, and doesn't have a lot of options (until recently), so that may explain the survival differences.
I like that theory about jumping hosts a lot better than the other commonly imagined one. You know, the one about it being an STD.  |
Hep C is not a big story because you live in the USA. It is a huge issue in emerging markets (particularly in asia) which is where pharma is focusing right now.
xtsukiyox: Brock Landers is absolutely correct in that clinical trials are global and have sites from many different countries in the world with the goal of getting a simultaneous (or as close to possible) approval in the EU, USA, Japan.
US policy is a deciding factor in drug approval for some pretty obvious reasons (1) it is the largest single market for most drugs and (2) the FDA (for all the bashing) is an excellent institution and is a bell weather for the rest of the world